REUMASPIS
PRODUCT INFORMATION
Reumaspis includes ingredients that help to manage the symptoms of fibromyalgia and diffuse arthralgy, reducing pain and sensitivity.
Reumaspis contains specially produced red ginseng, which offers anti-inflammatory and antioxidant action. The antioxidant action of red ginseng is enhanced by astaxanthin, providing the necessary antioxidant mechanism. Astaxanthin, which is included in the product, is literally hundreds of times stronger than other antioxidant molecules. Astaxanthin comes from the algae of the genus Haematococcus pluvialis and is a natural carotenoid.
Reumaspis includes ingredients with a positive effect on the patient’s mood. The main ingredient with the above action is the stigma of Crocus sativus L, which is a plant with a long history and use. Lastly, Reumaspis contains magnesium*, vitamin D3* and B12, ingredients that contribute to the normal function of bones.
*Health claims according to (EU) Regulation 432/2012: Vitamin D and magnesium to the maintenance of normal bones
ADVANTAGES
Reumaspis includes ingredients that act in synergy and help to:
- Reduce pain and sensitivity
- Reduce stiffness
- The management of depression
- Maintain bone health
INDICATIONS
Reumaspis based on its formulation, is addressed to patients with::
- Fibromyalgia
- Diffuse arthralgy
RECOMMENDED DOSAGE
Dosage: 1 tablet per day.
CHARACTERISTICS
- 100% natural product
- Compatible with medication
- Clinically proven ingredients
- No side effects
- Non-GMO
- Gluten free
- No sugar
Commercial rights & brand holder: Aniva International S.A.
Food supplements should not be used as a substitute of a well-balanced diet. This product is not intended to prevent, treat or cure any human disease. If you are pregnant, nursing, taking medication, or have medical condition, consult your physician before using this product. Keep out of reach of children. This dietary supplement should not be consumed by infants, children and adolescents under 14 years of age. Not recommended for population under antidepressant and antidiabetic treatment.
Notification number National Agency of Medicine, Greece : 62384 / 8-6-2023